Please provide your email address to receive an email when new articles are posted on . CHICAGO — Although cement augmentation did not alter the rate of secondary fracture after osteoporotic ...

Vertebral compression fractures are a significant morbidity and mortality related outcome of both primary and secondary osteoporosis. [1–3] Approximately 10 million Americans older than 50 have ...

Please provide your email address to receive an email when new articles are posted on . Unilateral balloon kyphoplasty was found to produce outcomes comparable to those of bilateral balloon ...

Osteoporosis is a common cause of spinal compression fracture in our society. The treatment should address both the associated pain and the underlying process of osteoporosis to prevent further ...

Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures in early postmenopausal women, a randomized trial showed. Over 10 years of ...

The researchers found that 6.3, 6.6, and 11.1% of the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo groups, respectively, had a new morphometric fracture at follow-up. HealthDay ...

Osteoporotic vertebral fractures (VF) occur in both sexes, but few studies have investigated the condition in men. In spinal radiographs, VF and non-osteoporotic vertebral deformities can appear ...

Nitrogen-containing bisphosphonates revolutionized osteoporosis treatment with the introduction of alendronate in 1995, risedronate in 2000, and ibandronate in 2003. Each of these agents was initially ...

Osteoporosis is a disease characterized by microarchitectural deterioration and bone loss, resulting in bone fragility. The primary clinical consequence of osteoporosis is fragility fracture, which in ...

Following an infusion of zoledronate acid in low-risk postmenopausal women, fracture risk reduction emerged only 5-10 years later in a placebo-controlled trial. By year 10, those who received a single ...

Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...